Terns Pharmaceuticals, Inc.
TERN
$2.92
-$0.13-4.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.95M | 9.77M | 7.19M | 6.86M | 6.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.95M | 24.94M | 25.54M | 25.45M | 24.06M |
| Operating Income | -25.95M | -24.94M | -25.54M | -25.45M | -24.06M |
| Income Before Tax | -21.76M | -21.88M | -22.68M | -22.28M | -20.97M |
| Income Tax Expenses | 40.00K | 62.00K | 61.00K | 97.00K | 49.00K |
| Earnings from Continuing Operations | -21.80M | -21.95M | -22.74M | -22.37M | -21.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.80M | -21.95M | -22.74M | -22.37M | -21.02M |
| EBIT | -25.95M | -24.94M | -25.54M | -25.45M | -24.06M |
| EBITDA | -25.88M | -24.86M | -25.45M | -25.36M | -23.99M |
| EPS Basic | -0.24 | -0.28 | -0.31 | -0.30 | -0.29 |
| Normalized Basic EPS | -0.15 | -0.18 | -0.19 | -0.19 | -0.18 |
| EPS Diluted | -0.24 | -0.28 | -0.31 | -0.30 | -0.29 |
| Normalized Diluted EPS | -0.15 | -0.18 | -0.19 | -0.19 | -0.18 |
| Average Basic Shares Outstanding | 91.24M | 77.82M | 74.46M | 74.40M | 72.33M |
| Average Diluted Shares Outstanding | 91.24M | 77.82M | 74.46M | 74.40M | 72.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |